The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.

ABSTRACT:

Background

Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment of migraine. However, there is no comprehensive literature to study the efficacy and safety of atogepant for the treatment of migraine. In this article, we present a meta-analysis of the available studies.

Methods

MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov were searched before October 20, 2021 for any relevant literature. Eventually, three randomized clinical trials (RCTs) with 2,466 patients were included in our study.

Results

We pooled 2,466 patients from 3 R

SUBMITTER: Tao X 

PROVIDER: S-EPMC8903713 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature